Chemotherapy agents are used as an effective disease-modifying treatment for Multiple Sclerosis.
Chemotherapy-based conditioning regimens used in procedures like autologous hematopoietic stem cell transplantation and potent immunosuppressive disease-modifying treatments serve as effective strategies to manage and alter the disease course in multiple sclerosis.
The retrieved papers consistently demonstrate that chemotherapy-based conditioning regimens (such as those used in autologous hematopoietic stem cell transplantation) and various disease-modifying therapies act as effective, disease-modifying treatments for multiple sclerosis by targeting underlying immune mechanisms and reducing relapses. There are no papers refuting the premise.
Cencioni MT, Genchi A, Brittain G, de Silva TI, Sharrack B, Snowden JA, Alexander T, Greco R, Muraro PA. Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party.. 2021. https://doi.org/10.3389/fimmu.2021.813957
Autologous hematopoietic stem cell transplantation uses intensive chemotherapy regimens to eradicate autoreactive immune cells and induce long-term remission in multiple sclerosis.
See more details
Brittain G, Roldan E, Alexander T, Saccardi R, Snowden JA, Sharrack B, Greco R. The Role of Chimeric Antigen Receptor T-Cell Therapy in Immune-Mediated Neurological Diseases.. 2024. https://doi.org/10.1002/ana.27029
Intense chemotherapy-based approaches such as autologous hematopoietic stem cell transplantation serve as effective treatments for immune-mediated neurological diseases.
Silfverberg T, Zjukovskaja C, Noui Y, Carlson K, Burman J. BEAM or cyclophosphamide in autologous haematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis.. 2024. https://doi.org/10.1038/s41409-024-02397-x
Chemotherapy conditioning regimens like BEAM and cyclophosphamide are utilized in autologous hematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis.
Kurilin V, Fisher M, Obleukhova I, Sennikov S. Cellular Immunotherapies for Multiple Sclerosis: Mechanistic Insights and Clinical Advances.. 2026. https://doi.org/10.3390/ijms27020585
Cellular immunotherapies and targeted treatments involving potent immunosuppressive and lympho-ablative agents modify the immunopathogenesis of multiple sclerosis.
Filippini G, Kruja J, Del Giovane C. Rituximab for people with multiple sclerosis.. 2025. https://doi.org/10.1002/14651858.cd013874.pub3
Rituximab and other off-label disease-modifying therapies effectively reduce relapses in multiple sclerosis.
Rocksy Fransisca V Situmeang, Nadia Gabriella. Disease-Modifying Therapy (DMT) Switch in Highly Active Multiple Sclerosis: A Case Report. 2025. https://doi.org/10.56951/jx5d6764
Immune-reconstitution disease-modifying therapies, including potent medications like cladribine, help achieve no evidence of disease activity in highly active multiple sclerosis.
The paper trail · every fact has a biography
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work · Dispute this receipt